AngioDynamics (NASDAQ:ANGO – Get Free Report) and Omnicell (NASDAQ:OMCL – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.
Institutional & Insider Ownership
89.4% of AngioDynamics shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 6.0% of AngioDynamics shares are owned by insiders. Comparatively, 2.9% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares AngioDynamics and Omnicell’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AngioDynamics | -10.12% | -4.49% | -2.96% |
| Omnicell | 3.59% | 5.69% | 3.61% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AngioDynamics | $320.17 million | 1.51 | -$36.74 million | ($0.78) | -14.73 |
| Omnicell | $1.18 billion | 1.32 | $2.05 million | $0.96 | 35.42 |
Omnicell has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations and price targets for AngioDynamics and Omnicell, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AngioDynamics | 1 | 1 | 2 | 1 | 2.60 |
| Omnicell | 0 | 2 | 7 | 1 | 2.90 |
AngioDynamics presently has a consensus price target of $19.00, indicating a potential upside of 65.36%. Omnicell has a consensus price target of $57.86, indicating a potential upside of 70.17%. Given Omnicell’s stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than AngioDynamics.
Volatility and Risk
AngioDynamics has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500.
Summary
Omnicell beats AngioDynamics on 11 of the 13 factors compared between the two stocks.
About AngioDynamics
AngioDynamics, Inc. develops, manufactures and markets medical devices used in minimally invasive procedures. Its products are designed for clinicians in areas including vascular access, peripheral vascular disease and oncology. The company’s offerings include vascular access devices such as ports and catheters, as well as technologies used in vascular intervention and cancer treatment. These include the Auryon atherectomy system, which is used to treat certain peripheral arterial conditions, and the NanoKnife System, which uses irreversible electroporation in tumor ablation procedures.
About Omnicell
Omnicell, Inc. develops medication-management solutions for healthcare providers. Its products and services are designed to help manage medication storage, dispensing, inventory and workflows across healthcare settings. The company offers automated dispensing cabinets for patient-care areas, automation systems for central pharmacies, and software and analytics that support medication management. Its solutions serve hospitals, health systems, pharmacies and other care providers, including long-term and post-acute care organizations.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
